科济药业(股票代码:02171)近日与相关方达成战略合作,计划对其位于上海金山区的CAR-T细胞治疗商业化生产基地进行产能扩建。此次合作旨在提升CAR-T疗法的规模化生产能力,满足日益增长的市场需求。通过扩建生产基地,科济药业将进一步加强其在细胞治疗领域的商业化布局,为未来产品上市提供坚实的生产保障。
科济药业(股票代码:02171)近日与相关方达成战略合作,计划对其位于上海金山区的CAR-T细胞治疗商业化生产基地进行产能扩建。此次合作旨在提升CAR-T疗法的规模化生产能力,满足日益增长的市场需求。通过扩建生产基地,科济药业将进一步加强其在细胞治疗领域的商业化布局,为未来产品上市提供坚实的生产保障。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.